International Journal of Hematology

, Volume 108, Issue 5, pp 554–557 | Cite as

Successful treatment of cytarabine-related neurotoxicity with corticosteroids, a case series

  • Jennifer L. DotsonEmail author
  • Muhammad Omer Jamil
Case Report


Neurotoxicity from high-dose cytarabine, a pyrimidine metabolite used in treatment for acute myeloid leukemia, is a known but dose-limiting toxicity which has incidences in up to 14% in patients receiving high doses of the drug. Neurologic symptoms vary but range from somnolence and ataxia to more severe complications such as seizures and even death. There are no validated treatments other than discontinuation of the drug and supportive measures. We present two cases of cytarabine-related neurotoxicity treated with corticosteroids with complete resolution of symptoms.


Cytarabine Acute myeloid leukemia Neurotoxicity 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Herzig RH, Hines JD, Herzig GP, Wolff SN, Cassileth PA, Lazarus HM, et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987;5(6):927–32.CrossRefPubMedGoogle Scholar
  2. 2.
    Stentoft J. The toxicity of cytarabine. Drug Saf. 1990;5(1):;7–27.CrossRefPubMedGoogle Scholar
  3. 3.
    Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. NEJM. 1994;331(14):896.CrossRefPubMedGoogle Scholar
  4. 4.
    Stone JB, DeAngelis LM. Cancer treatment-induced neurotoxicity: a focus on newer treatments. Nature Rev Clin Oncol. 2016;13(2):92–105.CrossRefGoogle Scholar
  5. 5.
    Salinsky MC, Levine RL, Aubuchon JP, Schutta HS. Acute cerebellar dysfunction with high-dose ARA-C therapy. Cancer. 1983;51:426–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Friedman JH, Shetty N. Permanent cerebellar toxicity of cytosine arabinoside (Ara C) in a young woman. Mov Disord. 2001;16(3):575.CrossRefPubMedGoogle Scholar
  7. 7.
    Lazarus HM, Herzig RH, Fishman DJ, Herzig GP, Phillips GL, Roessmann U. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer. 1981;48:2577–82.CrossRefPubMedGoogle Scholar
  8. 8.
    Lindner LH, Ostermann H, Hiddemann W, Kiana A, Wurfel M, et al. AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity. Int J Hematol. 2008;88:381–86.CrossRefPubMedGoogle Scholar
  9. 9.
    Baker WJ, Royer GL Jr, Weiss RB. Cytarabine and neurologic toxicity. J Clin Onc. 1991;9(4):679–93.CrossRefGoogle Scholar
  10. 10.
    Malhotra P, Mahi S, Lal V, Kumari S, Jain S, Varma S. Cytarabine-induced neurotoxicity responding to methyl prednisolone. Am J Hematol. 2004;77:416–22.CrossRefPubMedGoogle Scholar
  11. 11.
    Openshaw H, Slatkin NE, Stein AS, Hinton DR, Forman SJ. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer. 1996;78:1899–905.CrossRefPubMedGoogle Scholar
  12. 12.
    Zuckerman T, Ganzel C, Tallman MS, Rowe JM. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012;120(10):1993–2002.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  1. 1.Department of Hematology and OncologyMarshall UniversityHuntingtonUSA

Personalised recommendations